The Biotechnology Industry Organization (BIO) today announced the
selection of therapeutic workshops to be presented at the Twelfth Annual
BIO CEO & Investor Conference, taking place February 8-9 at the>
“This conference provides industry executives,
clinical thought leaders and investment professionals the opportunity to
discuss therapeutic areas of need and expectations for the next decade’s
market environment.”
“This year’s BIO CEO & Investor Conference will provide a unique forum
to showcase therapeutic areas with key catalysts – from new and dynamic
therapies to cutting edge investment opportunities,” said Alan
Eisenberg, executive vice president of Emerging Companies & Business
Development at BIO. “This conference provides industry executives,
clinical thought leaders and investment professionals the opportunity to
discuss therapeutic areas of need and expectations for the next decade’s
market environment.”
This year, BIO is collaborating with Panel Intelligence (formerly
MedPanel), a healthcare market research firm, to identify key opinion
leaders based on knowledge and expertise in their respective fields and
affiliations with prestigious academic institutions and medical
foundations.
The BIO CEO & Investor Conference’s therapeutic workshops will focus on
topics addressing the latest developments in therapies for a wide range
of diseases. This year’s therapeutic workshop topics include:
Sarcoma: Connecting the Dots on New Therapies
Monday,
February 8th, 9:00am-10:00am
-
John G. Curd, M.D.; President and Chief Medical Officer, Threshold
Pharmaceuticals
-
Jonathan Lewis, M.D., Ph.D., Chief Executive Officer and Chief Medical
Officer, ZIOPHARM Oncology
-
Robert G. Maki, M.D., Ph.D; Associate Member, Co-Leader, Adult Sarcoma
Program, Memorial Sloan-Kettering Cancer Center
RNAi Based Technology: No Longer Single & Stranded
Monday,
February 8, 12:30-1:35pm
-
Simos Simeonidis, PhD; Managing Director, Rodman & Renshaw, LLC
-
Noah D. Beerman, President and Chief Executive Officer, RXi
Pharmaceuticals
-
J. Michael French; Chief Executive Officer, MDRNA
-
Alnylam Pharmaceuticals
Alzheimer’s Disease: A Panel to Remember
Tuesday,
February 9th, 9:00am-10:00am